Pharmacology of Exenatide in Pediatric Sepsis

Withdrawn before enrolling · Phase 1/Phase 2

Conditions studied: Septic Shock, Inflammation, Glucose Homeostasis, Organ Dysfunction, Health-related Quality of Life

In brief

Pharmacology of Exenatide in Pediatric Sepsis, PEPS is a phase 1-2 research study that will examine drug safety, drug metabolism, drug action and preliminary drug clinical effects of four does of exenatide injected every 12 hours to children with shock from infection (septic shock). The investigators hypothesize that exenatide can be safely dosed to children with sepsis to achieve blood levels of drug similar to that achieved in teenagers with type 2 diabetes. The investigators further hypothesize that injection of exenatide to children with septic shock will normalize blood glucose levels and decrease levels of inflammation proteins in the blood during the early course of sepsis.

Key facts

Study ID

NCT01573806

Run by

Seattle Children's Hospital

People needed

0

Starts

2012-10-01

Expected to finish

2014-10-01

Last updated by the study team

2017-10-05

Who can join

Age: 0 and older, up to 18. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 44 weeks estimated gestational age to 18 years AND
• Admitted to the PICU for the sepsis event AND
• Vascular catheter capable of providing serial blood samples in place AND
• Diagnosis of septic shock = sepsis with cardiovascular organ dysfunction AND
• Parents speak English or Spanish

You may not qualify if…

• Greater than 12 hours from admission to PICU to enrollment OR
• Chronic or acute dialytic therapy, history of renal impairment or renal transplantation OR
• History of pancreatitis OR
• History of hypersensitivity to Byetta OR
• History of severe gastrointestinal disease or gastroparesis OR
• History of diabetes mellitus, type I or type II OR
• History of insulin, sulfonyl urea drugs, or coumarin use OR
• History of hypoglycemia OR
• History of active pregnancy (effect of exenatide on the fetus is unknown) OR
• Inability to collect serial blood samples OR
• Previously enrolled in the PEPS study OR
• Lack of commitment to aggressive sepsis therapy OR
• Expectation to succumb from the sepsis event OR
• Patient is a foster child and/or ward of the state OR
• Sepsis event associated with a PICU-acquired nosocomial infection OR
• Patient is enrolled in another interventional investigation that might obscure the potential effects of exenatide dosing.

Where it is running

• Seattle Children's Hospital — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.